OverviewCoherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.
|11/06/17||Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results|
|REDWOOD CITY, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2017.
Corporate Highlights for the Third Quarter 2017 Include:
Immunology (anti-TNF) therapeutic franchise:
CHS-0214 (etanercept (Enbrel®) biosimilar candidate)
- Filed petitions for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation o... |
|11/01/17||Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference|
|REDWOOD CITY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be participating in a fireside chat at the Credit Suisse Scottsdale Healthcare Conference on Tuesday, November 7, 2017 at 4:45pm ET being held in Scottsdale, AZ.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a... |
|10/23/17||Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th|
|REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2017 financial results will be released after market close on Monday, November 6th, 2017. Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing third quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://in... |
|09/07/17||Coherus BioSciences Provides Update on ‘619 IPR Institution Decision|
|Patent Trial and Appeal Board Denies Institution
REDWOOD CITY, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office denied institution of all four of its petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 9,085,619 (“the ‘619 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.
“While we are disappointed by this outcome, we c... |
|There are currently no events scheduled.|
Receive E-mail Alerts
|Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.|